204 related articles for article (PubMed ID: 10881027)
1. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
[TBL] [Abstract][Full Text] [Related]
7. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
Milovanovic SR; Radulovic S; Groot K; Schally AV
Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
[TBL] [Abstract][Full Text] [Related]
12. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
Int J Cancer; 2004 Nov; 112(4):570-6. PubMed ID: 15382037
[TBL] [Abstract][Full Text] [Related]
13. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
18. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
[TBL] [Abstract][Full Text] [Related]
20. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
